Dyskinesia pp 174-181 | Cite as

Differential Alteration of Striatal D-1 and D-2 Receptors Induced by the Long-Term Administration of Haloperidol, Sulpiride or Clozapine to Rats

  • P. Jenner
  • N. M. J. Rupniak
  • C. D. Marsden
Part of the Psychopharmacology Supplementum book series (PSYCHOPHARM, volume 2)


Rats received haloperidol, sulpiride, or clozapine in their daily drinking water for up to 1 year in clinically equivalent doses. After 12 months’ drug intake, and while drug administration continued, striatal dopamine function was assessed. Haloperidol induced D-2 receptor hypersensitivity as shown by enhanced apomorphine-induced stereotypy, elevated Bmax for specific 3H-spiperone and 3H-NPA binding, and an increase in striatal acetylcholine content. D-1 receptor sites appeared unaffected, since dopamine-stimulated adenylate cyclase and specific 3H-piflutixol binding were not altered. In contrast, neither sulpiride nor clozapine enhanced apomorphine-induced stereotypy or increased Bmax for 3H-spiperone binding. Sulpiride, but not clozapine, increased Bmax for 3H-NPA binding; clozapine, but not sulpiride, elevated striatal acetyl choline concentrations. In general, both sulpiride and clozapine enhanced D-1 function as assessed by dopamine-stimulated adenylate cyclase or 3H-piflutixol binding. On acute administration sulpiride and clozapine appear to act at D-2 sites, but continuous chronic administration of these compounds does not result in the development of striatal D-2 receptor hypersensitivity. The absence of change in D-2 function during chronic treatment, coupled with an ability to enhance D-1 function, may contribute to the low incidence of tardive dyskinesia produced by these drugs in man.


Adenylate Cyclase Tardive Dyskinesia Neuroleptic Drug Haloperidol Administration Differential Alteration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Christensen AV (1983) Animal models for neuroleptic induced neurological dysfunction. In: Usdin E et al. (ed.) Catecholamines: Neuropharmacology and central nervous system — Therapeutic aspects. Liss, New York, pp 99–109Google Scholar
  2. Clow A, Jenner P, Marsden CD (1979) Changes in dopamine mediated behavior during one years neuroleptic administration. Eur J Pharmacol 57: 365–375PubMedCrossRefGoogle Scholar
  3. Clow A, Theodorou A, Jenner P, Marsden CD (1980a) Changes in rat striatal dopamine turnover and receptor activity during one years administration. Eur J Pharmacol 63: 135–144PubMedCrossRefGoogle Scholar
  4. Clow A, Theodorou A, Jenner P, Marsden CD (1980b) Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol 63: 145–157PubMedCrossRefGoogle Scholar
  5. Fleminger S, Rupniak NMJ, Hall MD, Jenner P, Marsden CD (1983) Changes in apomorphine-induced stereotypy, as a result of subacute neuroleptic treatment correlates with increased D-2 receptors but not with increases in D-1 receptors. Biochem Pharmacol 32: 2921–2927PubMedCrossRefGoogle Scholar
  6. Grigoriadis D, Seeman P (1984) The dopamine/neuroleptic receptor. Can J Neurol Sci 11 [Suppl 1]: 108–113PubMedGoogle Scholar
  7. Hauser D, Closse A (1978) 3H-Clozapine binding to rat brain membranes. Life Sci 23: 557–562PubMedCrossRefGoogle Scholar
  8. Hyttel J (1980) Further evidence that 3H-cis(Z)-flupenthixol binds to adenylate cyclase- associated dopamine receptors (D-l) in rat corpus striatum. Psychopharmacology 67: 107–109PubMedCrossRefGoogle Scholar
  9. Hyttel J (1981) Similarities between the binding of 3H-piflutixol and 3H-flupenthixol to rat striatal dopamine receptors in vitro. Life Sci 28: 563–569PubMedCrossRefGoogle Scholar
  10. Iorio LC, Barnett A, Leitz FH, Hauser VP, Korduba CA (1983) SCH 23390 a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226: 462–468PubMedGoogle Scholar
  11. Jenner P, Marsden CD (1984) Multiple dopamine receptors in brain and the pharmacological action of substituted benzamide drugs. Acta Psychiatr Scand 69 [Suppl 311]: 109–123CrossRefGoogle Scholar
  12. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96PubMedCrossRefGoogle Scholar
  13. Klawans HL Jr (1973) The pharmacology of tardive dyskinesia. Am J Psychiatry 130: 82–86PubMedGoogle Scholar
  14. Leysen JE (1981) Review on neuroleptic receptors: specificity and multiplicity on in vitro binding related to pharmacological activity. In: Usdin E, Dahl SG, Gram LF, Lingiaerde O (eds) Clinical pharmacology in psychiatry: neuroleptic and antidepressant research. MacMillan, London, pp 35–62Google Scholar
  15. Marsden CD, Tarsy D, Baldessarini RJ (1973) Spontaneous and drug induced movement disorders in psychiatric patients. In: Benson DF, Blummer D (eds) Psychiatric aspects of neurologic disease. Grunne and Stratton, New York, pp 219–266Google Scholar
  16. Muller P, Seeman P (1978) Dopaminergic supersensitivity after neuroleptics: time course and specificity. Psychopharmacology 60: 1–11PubMedCrossRefGoogle Scholar
  17. Murugaiah K, Fleminger S, Theodorou A, Jenner P, Marsden CD (1983a) Persistent increase in striatal dopamine stimulated adenylate cyclase activity persists for more than 6 months but disappears after 1 year following withdrawal from 18 months cis-flupenthixol intake. Biochem Pharmacol 32: 2495–2499PubMedCrossRefGoogle Scholar
  18. Murugaiah K, Theodorou A, Jenner P, Marsden CD (1983b) Alteration in cerebral dopamine function caused by administration of cis- or trans-flupenthixol for up to 18 months. Neuro- science 10: 811–819PubMedCrossRefGoogle Scholar
  19. Rupniak NMJ, Boyce S, Jenner P, Marsden CD (1984) Interpretation of changes in apomorphine-induced stereotyped behavior in rats receiving continuous administration of tri-fluoperazine for 15 months. Neuropharmacology (to be published)Google Scholar
  20. Scatton B (1982) Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity. J Pharmacol Exp Ther 220: 197–202PubMedGoogle Scholar
  21. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 230–313Google Scholar
  22. Stoof JC, Kebabian JW (1981) Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294: 366PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • P. Jenner
  • N. M. J. Rupniak
  • C. D. Marsden
    • 1
  1. 1.MRC Movement Disorders Research Group, University Department of Neurology and Parkinsons Disease Society Research CentreInstitute of Psychiatry and Kings College Hospital Medical SchoolLondonEngland

Personalised recommendations